On the Use of Co-Data in Clinical Trials

References

• Babb, J., Rogatko, A., and Zacks, S. (1998), “Cancer Phase I Clinical Trials: Efficient Dose Escalation With Overdose Control,” Statistics in Medicine, 17, 1103–1120.
   Google Scholar
• Baeten, D., Baraliakos, X., Braun, J., Sieper, J., Emery, P., van der Heijde, D., McInnes, I., van Laar, J., Landewé, R., Wordsworth, P., Wollenhaupt, J., Kellner, H., Paramarta, J., Wei, J., Brachat, A., Bek, S., Laurent, D., Li, Y., Wang, Y., Bertolino, A., Gsteiger, S., Wright, A., and Hueber, W. (2013), “Anti-Interleukin-17A Monoclonal Antibody Secukinumab in Treatment of Ankylosing Spondylitis: A Randomised, Double-Blind, Placebo-Controlled Trial,” Lancet, 382, 1705–1713.
   Google Scholar
• Berry, S., Carlin, B., Lee, J., and Müller, P. (2001), Bayesian Adaptive Methods for Clinical Trials, Boca Raton, FL: CRC Press.
   Google Scholar
• Chen, M., and Ibrahim, J. (2000), “Power Prior Distributions for Regression Models,” Statistical Science, 15, 46–60.
   Google Scholar
• ——— (2006), “The Relationship Between the Power Prior and Hierarchical Models,” Bayesian Analysis, 1, 551–574.
   Google Scholar
• Chugh, R., Wathen, K., Maki, R., Benjamin, R., Patel, R., Myers, P., Priebat, D., Reinke, D., Thomas, D., Keohan, M., Samuels, B., and Baker, L. (2009), “Phase II Multicenter Trial of Imatinib in 10 Histologic Subtypes of Sarcoma Using a Bayesian Hierarchical Statistical Model,” Journal of Clinical Oncology, 27, 3148–3153.
   Google Scholar
• Cox, D. (2006), Principles of Statistical Inference, Cambridge, UK: Cambridge University Press.
   Google Scholar
• Cox, D., and Donnelly, C. (2011), Principles of Applied Statistics, Cambridge, UK: Cambridge University Press.
   Google Scholar
• Demin, I., Hamren, B., Luttringer, O., Pillai, G., and Jung, T. (2012), “Longitudinal Model-Based Meta-Analysis in Rheumatoid Arthritis: An Application Toward Model-Based Drug Development,” Clinical Pharmacology and Therapeutics, 92, 251–261.
   Google Scholar
• DerSimonian, R., and Kacker, R. (2007), “Random-Effects Model for Meta-Analysis of Clinical Trials: An Update,” Contempory Clinical Trials, 28, 105–114.
   Google Scholar
• Diaconis, P., and Ylvisaker, D. (1984), “Quantifying Prior Opinion,” Bayesian Statistics (Proceedings of the Second Valencia International Meeting), 2, 133–148.
   Google Scholar
• Dias, S., Welton, N., Sutton, A., and Ades, A. (2011), “NICE DSU Technical Support Document 2: A Generalised Linear Modelling Framework for Pairwise and Network Meta-Analysis of Randomised Controlled Trials,” available at http://www.nicedsu.org.uk/TSD2%20General%20meta%20analysis%20corrected%2015April2014.pdf.
   Google Scholar
• Duan, Y., Ye, K., and Smith, E. (2006), “Evaluating Water Quality Using Power Priors to Incorporate Historical Information,” Environmetrics, 17, 95–106.
   Google Scholar
• Egger, M., Smith, G., and Altman, D. (1995), Systematic Reviews in Health Care: Meta-Analysis in Contect, London: BMJ Publishing Group.
   Google Scholar
• Eisenhauer, E., Twelves, C., and Buyse, M. (2006), Phase I Cancer Trials: A Practical Guide, New York: Oxford University Press.
   Google Scholar
• European Commission (2014), “Innovative Medicines Initiative 2: Europe’s Fast Track to Better Medicines,” available at http://ec.europa.eu/research/press/jti/factsheet_imi2-web.pdf.
   Google Scholar
• Food and Drug Administration (FDA) (2004), “Innovation/Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products,” available at http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/CriticalPathInitiative/CriticalPathOpportunitiesReports/UCM113411.pdf.
   Google Scholar
• ——— (2010), “Draft Guidance for Industry: Non-Inferiority Clinical Trials,” available at http://www.fda.gov/downloads/Drugs/.../Guidances/UCM202140.pdf.
   Google Scholar
• ——— (2013), “Paving the Way for Personalized Medicine: FDA’s Role in a New Era of Medical Product Development.,” available at http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/PersonalizedMedicine/UCM372421.pdf.
   Google Scholar
• ——— (2015), “Leveraging Existing Clinical Data for Extrapolation to Pediatric Uses of Medical Devices: Draft Guidance for Industry and Food and Drug Administration Staff,” available at http://www.fda.gov/ucm/groups/fdagov-public/@fdagov-meddev-gen/documents/document/ucm444591.pdf.
   Google Scholar
• 21st Century Cures Act. ( May 19, 2015), available at http://docs.house.gov/meetings/IF/IF00/20150519/103516/BILLS-1146ih.pdf.
   Google Scholar
• French, J., Wang, S., Warnock, B., and Temkin, N. (2010), “Historical Control Monotherapy Design in the Treatment of Epilepsy,” Epilepsia, 51, 1936–1943.
   Google Scholar
• Gallo, P., Mao, L., and Shih, V. (2014), “Alternative Views on Setting Clinical Trial Futility Criteria,” Journal of Biopharmaceutical Statistics, 24, 976–993.
   Google Scholar
• Gelman, A. (2006), “Prior Distributions for Variance Parameters in Hierarchical Models,” Bayesian Analysis, 1, 515–534.
   Google Scholar
• Goodman, S., and Sladky, J. (2005), “A Bayesian Approach to Randomized Controlled Trials in Children Utilizing Information From Adults: The Case of Guillain–Barre Syndrome,” Clinical Trials, 2, 305–310.
   Google Scholar
• Gsteiger, S., Neuenschwander, B., Mercier, F., and Schmidli, H. (2013), “Using Historical Control Information for the Design and Analysis of Clinical Trials With Overdispersed Count Data,” Statistics in Medicine, 32, 3609–3622.
   Google Scholar
• Higgins, J., and Green, S. (2006), Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0,” available at www.cochrane-handbook.org, Cambridge, UK: Cambridge University Press.
   Google Scholar
• Hobbs, B., Carlin, B., Mandrekar, S., and Sargent, D. (2011), “Hierarchical Commensurate and Power Prior Models for Adaptive Incorporation of Historical Information in Clinical Trials,” Biometrics, 67, 1047–1056.
   Google Scholar
• I-SPY (2015), available at http:/ispy.org.
   Google Scholar
• Kass, R., and Wasserman, L. (1995), “A Reference Bayesian Test for Nested Hypotheses and Its Relationship to the Schwarz Criterion,” Journal of the American Statistical Association, 90, 928–934.
   Google Scholar
• Katz, R. (2006), “FDA Update,” Epilepsy Research, 68, 85–94.
   Google Scholar
• Lindley, D. (2003), Making Decisions, New York: Wiley.
   Google Scholar
• ——— (2006), Understanding Uncertainty, New York: Wiley.
   Google Scholar
• Lunn, D., Jackson, C., Best, N., Thomas, A., and Spiegelhalter, D. (2012), The BUGS Book: A Practical Introduction to Bayesian Analysis, Boca Raton, FL: CRC Press.
   Google Scholar
• Lunn, D., Thomas, A., Best, N., and Spiegelhalter, D. (2000), “WinBUGS—A Bayesian Modelling Framework: Concepts, Structure, and Extensibility,” Statistics and Computing, 10, 325–337.
   Google Scholar
• Malec, D. (2001), “A Closer Look at Combining Data Among a Small Number of Binomial Experiments,” Statistics in Medicine, 20, 1811–1824.
   Google Scholar
• Morita, S., Thall, P., and Müller, P. (2008), “Determining the Effective Sample Size of a Parametric Prior,” Biometrics, 64, 595–602.
   Google Scholar
• Nedelman, J., Bretz, F., Fisch, R., Georgieva, A., Hsu, C., Kahn, J., Kawai, L., Lowe, P., Maca, J., Pinheiro, J., Rossini, A., Schmidli, H., Steimer, J., and Yu, J. (2010), “Modeling and Simulation in Clinical Drug Development,” Pharmaceutical Sciences Encyclopedia, 43, 1–29.
   Google Scholar
• Neuenschwander, B., Branson, M., and Spiegelhalter, D. (2009), “A Note on the Power Prior,” Statistics in Medicine, 28, 3562–3566.
   Google Scholar
• Neuenschwander, B., Capkun-Niggli, G., Branson, M., and Spiegehalter, D. (2010), “Summarizing Historical Information on Controls in Clinical Trials,” Clinical Trials, 7, 5–18.
   Google Scholar
• Neuenschwander, B., Matano, A., Tang, Z., Roychoudhury, S., Wandel, S., and Bailey, S. (2015a), “A Bayesian Industry Approach to Phase I Combination Trials in Oncology,” in Statistical Methods in Drug Combination Studies, eds. W. Zhao and H. Yang, Boca Raton, FL: Chapman & Hall/CRC Biostatistics Series.
   Google Scholar
• Neuenschwander, B., Wandel,S., Roychoudhury, S., and Bailey, S. (2015b), “Robust Exchangeability-Nonexchangeability Designs for Early Phase Oncology Trials With Multiple Strata,” Pharmaceutical Statistics, 15, 123–134.
   Google Scholar
• O’Hagan, A., and Forster, J. (2004), Kendall’s Advanced Theory of Statistics Vol 2B: Bayesian Inference, London: Arnold.
   Google Scholar
• Pennello, G., and Thompson, L. (2008), “Experience With Reviewing Bayesian Medical Device Trials,” Journal of Biopharmaceutical Statistics, 18, 81–115.
   Google Scholar
• Pocock, S. (1976), “The Combination of Randomized and Historical Controls in Clinical Trials,” Journal of Chronic Diseases, 29, 175–188.
   Google Scholar
• Schmidli, H., Gsteiger, S., Roychoudhury, S., O’Hagan, A., Spiegelhalter, D., and Neuenschwander, B. (2014), “Robust Meta-Analytic-Predictive Priors in Clinical Trials With Historical Control Information,” Biometrics, 70, 1023–32.
   Google Scholar
• Schmidli, H., Wandel, S., and Neuenschwander, B. (2013), “The Network Meta-Analytic-Predictive Approach to Non-Inferiority Trials,” Statistical Methods in Medical Research, 22, 219–240.
   Google Scholar
• Spiegelhalter, D., Abrams, K., and Myles, J. (2004), Bayesian Approaches to Clinical Trials and Health-Care Evaluation, New York: Wiley.
   Google Scholar
• Spiegelhalter, D., Freedman, L., and Bradburn, P. R. (1986), “Monitoring Clinical Trials: Conditional or Predictive Power?” Controlled Clinical Trials, 7, 8–17.
   Google Scholar
• Thall, P., Millikan, R., Müller, P., and Lee, S. (2003a), “Dose Finding With Two Agents in Phase I Oncology Trials,” Biometrics, 59, 487–496.
   Google Scholar
• Thall, P., Wathen, J., Bekele, B., Champlin, R., Baker, L., and Benjamin, R. (2003b), “Hierarchical Bayesian Approaches to Phase II Trials in Diseases With Multiple Subtypes,” Journal of Clinical Oncology, 22, 763–780.
   Google Scholar
• Turner, R. M., Jackson, D., Wei, Y., Thompson, S. G., and Higgins, J. P. T. ( 2015, MAR 15), “Predictive Distributions for Between-Study Heterogeneity and Simple Methods for Their Application in Bayesian Meta-Analysis,” Statistics in Medicine, 34, 984–998.
   Google Scholar
• Viele, K., Berry, S., Neuenschwander, B., Amzal, B., Chen, F., Enas, N., Hobbs, B., Ibrahim, J., Kinnersley, N., Lindborg, S., Micallef, S., Roychoudhury, S., and Thompson, L. (2014), “Use of Historical Control Data for Assessing Treatment Effects in Clinical Trials,” Pharmaceutical Statistics, 13, 41–54.
   Google Scholar
• Walley, R., Smith, C., Gale, J., and Woodward, P. (2015), “Advantages of a Wholly Bayesian Approach to Assessing Efficacy in Early Drug Development: A Case Study,” Pharmaceutical Statistics, 14, 205–215.
   Google Scholar
• Wang, M., Liu, G., and Schindler, J. (2015), “Evaluation of Program Success for Programs With Multiple Trials in Binary Outcomes,” Pharmaceutical Statistics, 3, 172–179.
   Google Scholar
• Wechsler, R., Li, G., French, J., O’Brien, T., William, P., Goodson, R., and Brock, M. (2014), “Conversion to Lacosamide Monotherapy in the Treatment of Focal Epilepsy: Results From a Historical-Controlled, Multicenter, Double-Blind Study,” Epilepsia, 55, 1088–1098.
   Google Scholar
• Zhou, X., Liu, S., Kim, E., Herbst, R., and Lee, J. (2008), “Bayesian Adaptive Design for Targeted Therapy Development in Lung Cancer: A Step Toward Personalized Medicine,” Clinical Trials, 5, 181–193.
   Google Scholar